Vitaspring Biomedical Co Stock Performance
| VSBC Stock | USD 1.00 0.00 0.00% |
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and VitaSpring Biomedical are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days VitaSpring Biomedical Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound fundamental drivers, VitaSpring Biomedical is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 45.4 K | |
| Total Cashflows From Investing Activities | 73 K |
VitaSpring |
VitaSpring Biomedical Relative Risk vs. Return Landscape
If you would invest 100.00 in VitaSpring Biomedical Co on November 5, 2025 and sell it today you would earn a total of 0.00 from holding VitaSpring Biomedical Co or generate 0.0% return on investment over 90 days. VitaSpring Biomedical Co is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than VitaSpring, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
VitaSpring Biomedical Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of VitaSpring Biomedical for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for VitaSpring Biomedical can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| VitaSpring Biomedical generated a negative expected return over the last 90 days | |
| VitaSpring Biomedical has some characteristics of a very speculative penny stock | |
| About 59.0% of the company outstanding shares are owned by insiders |
VitaSpring Biomedical Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of VitaSpring Pink Sheet often depends not only on the future outlook of the current and potential VitaSpring Biomedical's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. VitaSpring Biomedical's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 206 M | |
| Cash And Short Term Investments | 107.2 K |
VitaSpring Biomedical Fundamentals Growth
VitaSpring Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of VitaSpring Biomedical, and VitaSpring Biomedical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on VitaSpring Pink Sheet performance.
| Return On Equity | 0.84 | |||
| Return On Asset | 0.41 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.24 % | |||
| Current Valuation | 2.89 B | |||
| Shares Outstanding | 206.52 M | |||
| Price To Book | 1,622 X | |||
| Price To Sales | 558.27 X | |||
| Revenue | 5.61 M | |||
| EBITDA | 1.49 M | |||
| Cash And Equivalents | 21.59 K | |||
| Total Debt | 375.5 K | |||
| Debt To Equity | 0.21 % | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | 84.81 K | |||
| Total Asset | 3.6 M | |||
About VitaSpring Biomedical Performance
By analyzing VitaSpring Biomedical's fundamental ratios, stakeholders can gain valuable insights into VitaSpring Biomedical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if VitaSpring Biomedical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if VitaSpring Biomedical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
The company was formerly known as Shemn Corp. and changed its name to VitaSpring Biomedical Co. Ltd. was incorporated in 2016 and is headquartered in Irvine, California. Vitaspring Biomedical operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about VitaSpring Biomedical performance evaluation
Checking the ongoing alerts about VitaSpring Biomedical for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for VitaSpring Biomedical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| VitaSpring Biomedical generated a negative expected return over the last 90 days | |
| VitaSpring Biomedical has some characteristics of a very speculative penny stock | |
| About 59.0% of the company outstanding shares are owned by insiders |
- Analyzing VitaSpring Biomedical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether VitaSpring Biomedical's stock is overvalued or undervalued compared to its peers.
- Examining VitaSpring Biomedical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating VitaSpring Biomedical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of VitaSpring Biomedical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of VitaSpring Biomedical's pink sheet. These opinions can provide insight into VitaSpring Biomedical's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for VitaSpring Pink Sheet analysis
When running VitaSpring Biomedical's price analysis, check to measure VitaSpring Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VitaSpring Biomedical is operating at the current time. Most of VitaSpring Biomedical's value examination focuses on studying past and present price action to predict the probability of VitaSpring Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VitaSpring Biomedical's price. Additionally, you may evaluate how the addition of VitaSpring Biomedical to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |